Search results
Results from the WOW.Com Content Network
Registration required for manufacturing, distribution, import, or export X ... MDMA and other "ecstasy"-type substances 3,4-MDP-2-P methyl glycidic acid (PMK glycidic ...
Getting MDMA in front of FDA regulators was the culmination of decades of advocacy by the ... These protocols could include licensing and registration requirements for providers and patients ...
MDMA and metabolites are primarily excreted as conjugates, such as sulfates and glucuronides. [214] MDMA is a chiral compound and has been almost exclusively administered as a racemate. However, the two enantiomers have been shown to exhibit different kinetics.
MDMA/citalopram is a combination of the entactogen and monoamine releasing agent 3,4-methylenedioxymethamphetamine (MDMA; also known as midomafetamine or "ecstasy") and the selective serotonin reuptake inhibitor (SSRI) citalopram which is under development for the treatment of post-traumatic stress disorder (PTSD).
Commonly known as ecstasy or molly, MDMA has long been seen by advocates as a potential treatment for mental health disorders and to have therapeutic applications beyond its illicit use.
EMDL organized supporters to petition the DEA for a scheduling hearing regarding MDMA. George Greer, Lester Grinspoon, Professor James Bakalar, and Professor Thomas Roberts contributed to the argument that MDMA belonged in Schedule III, a category that would more readily enable future research and permit the continuation of its use in ...
Lykos Therapeutics, formerly known as the MAPS Public Benefit Corporation (MAPS PBC), is a public benefit corporation (PBC) that is developing MDMA ("ecstasy") as a potential medicine. [1] It was founded and is considerably owned by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). [ 1 ]
The base compound of the MDxx class is 3,4-methylenedioxyphenethylamine (MDPEA), and the prototypical agent of this class is 3,4-methylenedioxy-N-methylamphetamine (MDMA; "ecstasy").